Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 16/20 | 0.68 |
| ▸ | PSEN2 | P49810 | 16/20 | 0.68 |
| ▸ | APH1B | Q8WW43 | 16/20 | 0.68 |
| ▸ | NCSTN | Q92542 | 16/20 | 0.68 |
| ▸ | APH1A | Q96BI3 | 16/20 | 0.68 |
| ▸ | PSENEN | Q9NZ42 | 16/20 | 0.68 |
| ▸ | APP | P05067 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.68 |
| ▸ | RORC | P51449 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12126921 | 1.00 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29536448 | 1.00 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8257641 | 0.91 | PSEN1 (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3800634 | 0.90 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12126925 | 0.84 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15693566 | 0.84 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1338727 | 0.84 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8246926 | 0.83 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Mrk-560 SCHEMBL237759 | 0.81 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Mrk-560 SCHEMBL237760 | 0.81 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458076-B1 | HUMAN AIRWAY STEM CELLS IN LUNG EPITHELIAL ENGINEERING | MASSACHUSETTS GEN HOSPITAL (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-09-23 | — | — | US | disclosed |
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12161647-B2 | Treating hearing loss | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2024-12-10 | — | — | US | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11963968-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2014039908-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2014-03-13 | — | — | WO | disclosed |
| US-8609897-B2 | Trifluoromethylsulfonamide gamma secretase inhibitor | MERCK SHARP & DOHME CORP. (US) | 2013-12-17 | — | — | US | disclosed |
| EP-2393776-A1 | NOVEL TRIFLUOROMETHYLSULFONAMIDE GAMMA SECRETASE INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20110275719-A1 | NOVEL TRIFLUOROMETHYLSULFONAMIDE GAMMA SECRETASE INHIBITOR | MERCK SHARP & DOHME LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275719-A1 | NOVEL TRIFLUOROMETHYLSULFONAMIDE GAMMA SECRETASE INHIBITOR | MERCK SHARP & DOHME LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275719-A1 | NOVEL TRIFLUOROMETHYLSULFONAMIDE GAMMA SECRETASE INHIBITOR | MERCK SHARP & DOHME LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110263580-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| EP-2375895-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | Merck Sharp & Dohme Corp. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010090954-A1 | NOVEL TRIFLUOROMETHYLSULFONAMIDE GAMMA SECRETASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010068564-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419876-B2 | Treatment of hearing loss by inhibition of casein kinase 1 | GSK3B, GSKIP, BACE1 | PSEN1 21/4885PSEN2 36/4885APH1B 78/4885 |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | PSEN1 170/4885PSEN2 319/4885APH1B 37/4885 |
| US-12161647-B2 | Treating hearing loss | BACE1, BACE2, PSENEN | PSEN1 9/4885PSEN2 10/4885APH1B 4/4885 |
| US-20110263580-A1 | METHOD FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS | BACE1, BACE2, APP | PSEN1 4/4885PSEN2 5/4885APH1B 7/4885 |
| US-20110275719-A1 | NOVEL TRIFLUOROMETHYLSULFONAMIDE GAMMA SECRETASE INHIBITOR | BACE1, BACE2, APH1B | PSEN1 7/4885PSEN2 13/4885APH1B 3/4885 |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | PSEN1 1051/4885PSEN2 2053/4885APH1B 434/4885 |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | HES1, NOTCH1, NOTCH4 | PSEN1 169/4885PSEN2 239/4885APH1B 164/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | PSEN1 169/4885PSEN2 239/4885APH1B 164/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | PSEN1 170/4885PSEN2 319/4885APH1B 37/4885 |
| US-11963968-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | PSEN1 170/4885PSEN2 319/4885APH1B 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.